Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

Details 詳細情報について

• CRID

  1363670321181983488

• DOI

  10.1007/s10549-014-2923-9

• ISSN

  15737217

  01676806

• Web Site

  http://link.springer.com/content/pdf/10.1007/s10549-014-2923-9.pdf

  http://link.springer.com/article/10.1007/s10549-014-2923-9/fulltext.html

  http://link.springer.com/content/pdf/10.1007/s10549-014-2923-9

• Data Source

  • Crossref